Pfizer (PFE) Receives FDA Priority Review for Expanded Use of PADCEV in Bladder Cancer Treatment
Pfizer Inc. (NYSE:PFE), together with Astellas Pharma, received a Priority Review from the FDA for an expanded indication of its drug PADCEV combined with Keytruda as perioperative treatment for muscle-invasive bladder cancer patients. The decision could broaden access to this regimen and potentially enhance Pfizer's market position in oncology.
Tickers: $PFE
Topics: bladder cancer FDA medical stocks pharmaceuticals Priority Review